Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (CYCCP)

7.05
0.05 0.71
NASDAQ
Prev Close 7.00
Open 7.05
Day Low/High 7.05 / 7.05
52 Wk Low/High 3.60 / 7.08
Volume 200.00
Exchange NASDAQ
Shares Outstanding 335.00M
Market Cap 2.35M
Div & Yield N.A. (N.A)

Latest News

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Cyclacel Announces Reverse Stock Split

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Company to Present at the Biotech Showcase(TM) 2016 Conference

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST

Data To Be Presented On CYC065, Cyclacel's CDK2/9 Inhibitor, At AACR-NCI-EORTC International Conference

Data To Be Presented On CYC065, Cyclacel's CDK2/9 Inhibitor, At AACR-NCI-EORTC International Conference

Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology

Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results

Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results

Conference Call Scheduled August 11, 2015 at 4:30 p.m. EDT

First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder

First Patient Dosed In IST Of CDK Inhibitor Seliciclib In Cushing's Disease, A Serious Endocrine Disorder

- Unique Dual Action Through Inhibition of Cyclin E and ACTH Production in Pituitary Tumors -

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis

Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development Of Seliciclib In Cystic Fibrosis

Novel CDK Inhibitor-Based Approach to Treat Cystic Fibrosis